Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.
<h4>Background</h4>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has recently been identified as the causative agent for Coronavirus Disease 2019 (COVID-19). The ability of this agent to be transmitted by blood transfusion has not been documented, although viral RNA has be...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0233947 |
| _version_ | 1819134499760373760 |
|---|---|
| author | Izabela Ragan Lindsay Hartson Heather Pidcoke Richard Bowen Raymond Goodrich |
| author_facet | Izabela Ragan Lindsay Hartson Heather Pidcoke Richard Bowen Raymond Goodrich |
| author_sort | Izabela Ragan |
| collection | DOAJ |
| description | <h4>Background</h4>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has recently been identified as the causative agent for Coronavirus Disease 2019 (COVID-19). The ability of this agent to be transmitted by blood transfusion has not been documented, although viral RNA has been detected in serum. Exposure to treatment with riboflavin and ultraviolet light (R + UV) reduces blood-borne pathogens while maintaining blood product quality. Here, we report on the efficacy of R + UV in reducing SARS-CoV-2 infectivity when tested in human plasma and whole blood products.<h4>Study design and methods</h4>SARS-CoV-2 (isolate USA-WA1/2020) was used to inoculate plasma and whole blood units that then underwent treatment with riboflavin and UV light (Mirasol Pathogen Reduction Technology System, Terumo BCT, Lakewood, CO). The infectious titers of SARS-CoV-2 in the samples before and after R + UV treatment were determined by plaque assay on Vero E6 cells. Each plasma pool (n = 9) underwent R + UV treatment performed in triplicate using individual units of plasma and then repeated using individual whole blood donations (n = 3).<h4>Results</h4>Riboflavin and UV light reduced the infectious titer of SARS-CoV-2 below the limit of detection for plasma products at 60-100% of the recommended energy dose. At the UV light dose recommended by the manufacturer, the mean log reductions in the viral titers were ≥ 4.79 ± 0.15 Logs in plasma and 3.30 ± 0.26 in whole blood units.<h4>Conclusion</h4>Riboflavin and UV light effectively reduced the titer of SARS-CoV-2 to the limit of detection in human plasma and by 3.30 ± 0.26 on average in whole blood. Two clades of SARS-CoV-2 have been described and questions remain about whether exposure to one strain confers strong immunity to the other. Pathogen-reduced blood products may be a safer option for critically ill patients with COVID-19, particularly those in high-risk categories. |
| first_indexed | 2024-12-22T10:04:10Z |
| format | Article |
| id | doaj.art-7a737b5354384d868ab6d023f5e0a7e1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T10:04:10Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7a737b5354384d868ab6d023f5e0a7e12022-12-21T18:30:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01155e023394710.1371/journal.pone.0233947Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.Izabela RaganLindsay HartsonHeather PidcokeRichard BowenRaymond Goodrich<h4>Background</h4>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has recently been identified as the causative agent for Coronavirus Disease 2019 (COVID-19). The ability of this agent to be transmitted by blood transfusion has not been documented, although viral RNA has been detected in serum. Exposure to treatment with riboflavin and ultraviolet light (R + UV) reduces blood-borne pathogens while maintaining blood product quality. Here, we report on the efficacy of R + UV in reducing SARS-CoV-2 infectivity when tested in human plasma and whole blood products.<h4>Study design and methods</h4>SARS-CoV-2 (isolate USA-WA1/2020) was used to inoculate plasma and whole blood units that then underwent treatment with riboflavin and UV light (Mirasol Pathogen Reduction Technology System, Terumo BCT, Lakewood, CO). The infectious titers of SARS-CoV-2 in the samples before and after R + UV treatment were determined by plaque assay on Vero E6 cells. Each plasma pool (n = 9) underwent R + UV treatment performed in triplicate using individual units of plasma and then repeated using individual whole blood donations (n = 3).<h4>Results</h4>Riboflavin and UV light reduced the infectious titer of SARS-CoV-2 below the limit of detection for plasma products at 60-100% of the recommended energy dose. At the UV light dose recommended by the manufacturer, the mean log reductions in the viral titers were ≥ 4.79 ± 0.15 Logs in plasma and 3.30 ± 0.26 in whole blood units.<h4>Conclusion</h4>Riboflavin and UV light effectively reduced the titer of SARS-CoV-2 to the limit of detection in human plasma and by 3.30 ± 0.26 on average in whole blood. Two clades of SARS-CoV-2 have been described and questions remain about whether exposure to one strain confers strong immunity to the other. Pathogen-reduced blood products may be a safer option for critically ill patients with COVID-19, particularly those in high-risk categories.https://doi.org/10.1371/journal.pone.0233947 |
| spellingShingle | Izabela Ragan Lindsay Hartson Heather Pidcoke Richard Bowen Raymond Goodrich Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS ONE |
| title | Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. |
| title_full | Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. |
| title_fullStr | Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. |
| title_full_unstemmed | Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. |
| title_short | Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. |
| title_sort | pathogen reduction of sars cov 2 virus in plasma and whole blood using riboflavin and uv light |
| url | https://doi.org/10.1371/journal.pone.0233947 |
| work_keys_str_mv | AT izabelaragan pathogenreductionofsarscov2virusinplasmaandwholebloodusingriboflavinanduvlight AT lindsayhartson pathogenreductionofsarscov2virusinplasmaandwholebloodusingriboflavinanduvlight AT heatherpidcoke pathogenreductionofsarscov2virusinplasmaandwholebloodusingriboflavinanduvlight AT richardbowen pathogenreductionofsarscov2virusinplasmaandwholebloodusingriboflavinanduvlight AT raymondgoodrich pathogenreductionofsarscov2virusinplasmaandwholebloodusingriboflavinanduvlight |